BIO Comments on the Diverse and Equitable Participation in Clinical Trials (DEPICT) Act
December 6, 2021
BIO is committed to enhancing clinical trial diversity as part of our BIOEquality Agenda published in the fall of 2020. During the pandemic we witnessed biopharmaceutical companies achieve increased clinical trial diversity through commitment and regulatory acceptance of certain clinical development tools and approaches. We appreciate the opportunity to provide feedback on the draft legislation.
Dear Colleagues, I am just past the two-year mark as BIO’s President & CEO, which arrives as we find ourselves at a defining moment for the future of biotechnology. For fifty years, our industry has delivered one of the great…
BIO is committed to enhancing clinical trial diversity as part of our BIOEquality Agenda published in the fall of 2020. During the pandemic we witnessed biopharmaceutical companies achieve increased clinical trial diversity through commitment and regulatory acceptance of certain clinical development tools and approaches. We appreciate the opportunity to provide feedback on the draft legislation.